Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley, Chirag R Jani, Craig Mescher, Shabana J Dewani, Ursa Brown-Glaberman, Lisa E Flaum, Erica L Mayer, William M Sikov, Eve T Rodler, Angela M DeMichele, Joseph A Sparano, Antonio C Wolff, Kathy D Miller, Lynne I Wagner
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Northwestern University, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, The University of Texas MD Anderson Cancer Center, Michigan Cancer Research Consortium, Montefiore Medical Center, Trinity Health Ann Arbor Hospital, Phoebe Putney Memorial Hospital, Metro-Minnesota Community Oncology Research Consortium, Columbus Oncology and Hematology Associates, UNM Comprehensive Cancer Center, Women & Infants Hospital of Rhode Island, University of California, Davis, Abramson Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Wake Forest University Health Sciences
Language: English
Topic: Cancer survivorship and care
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4220959547